title: Myostatin as a therapeutic target in Amyotrophic lateral sclerosis.
abstract: Amyotrophic Lateral Sclerosis is a devastating neurological disease that is inevitably fatal after 3-5years duration. Treatment options are minimal and as such new therapeutic modalities are required. In this review, we discuss the role of the myostatin pathway as a modulator of skeletal muscle mass and therapeutic approaches using biological based therapies. Both monoclonal antibodies to myostatin and a soluble receptor decoy to its high affinity receptor have been used in clinical trials of neuromuscular diseases and while there have been efficacy signals with the latter approach there have also been safety issues. Our approach is to target the high affinity receptor-binding site on myostatin and to develop a next generation set of therapeutic reagents built on a novel protein scaffold. This is the natural single domain VNAR found in sharks which is extremely versatile and has the ability to develop products with superior properties compared to existing therapeutics.
authors: Ossianix Inc., 3711 Market St., Philadelphia, PA 19104, USA. walsh@ossianix.com
authors: Frank S
authors: FS
authors: Walsh
authors: Julia Lynn
authors: JL
authors: Rutkowski
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000378:metabolism / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D055435:Myostatin / Q000187:drug effects* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D055435:Myostatin